EL7.AI
StocksMediumUpdated×3•Originally published 30 March 2026•Updated 31 March 2026•
1 min read

Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion to Expand Rare Disease Portfolio

Key Facts

1The U.S. FDA approved a higher-dose version of Biogen's drug for a rare genetic disorder that causes progressive muscle weakness.

Biogen has reached an agreement to acquire Apellis Pharmaceuticals for approximately $5.6 billion in an all-cash transaction. This strategic move follows the recent FDA approval of a higher-dose formulation of Biogen's Spinraza, a key treatment for Spinal Muscular Atrophy (SMA). The acquisition marks a significant shift for Biogen (BIIB) as it moves from organic growth to inorganic expansion to bolster its rare disease franchise. By integrating Apellis, Biogen aims to diversify its revenue streams and mitigate competition in the specialized drug market. Analysts view the deal as a critical step in extending the company's long-term commercial lifecycle and strengthening its competitive positioning. This multi-billion dollar investment is expected to enhance investor confidence in Biogen's ability to drive sustainable growth through strategic M&A.